As a part of systematic investigation of the synthesis and biological activities of pyrazole analogues linked to various heterocyclic systems, a new series of pyrazolo-N-glycoside derivatives, pyrazolopyranopyrimidine and C-glycoside of pyrazolopyranotriazolo-pyrimidine derivatives was synthesized through the reaction of the key intermediate
Nucleoside analogs play an important role in anticancer chemotherapy (1) . Cancer cells display a strong ability of acquiring resistance to antitumor drugs, termed multidrug resistance (MDR), which is a critical hurdle to cancer therapy. For this reason, the discovery and development of new types of highly selective anticancer agents is still a very urgent topic. Pyrazolone nucleus has att racted much att ention due to its interesting biological activities (2) (3) (4) (5) . The chemistry of pyrazole derivatives received great att ention because of their biological activities as potential HIV-1 inhibitors (6), insecticides, fungicides (7) , antiviral agents (8) and anticancer activity (9) . On the other hand, fused pyrazoles such as pyranopyrazoles are an important class of biologically active heterocycles. They have been reported to possess a multiplicity of pharmacological properties, including anticancer (10), antimicrobial (11) , antiinfl ammatory (12) , insecticidal and molluscicidal activities (13, 14) . They are also potential inhibitors of human Chk1 kinase (15) and can fi nd applications as pharmaceutical ingredients and biodegradable agrochemicals (16) .
In the course of our ongoing research on modifi ed heterocyclic and nucleoside analogs, we became interested in a stereo-selective strategy for the preparation of N-nucleosides. Moreover, the increasing biological importance of pyranopyrazole derivatives, particularly in chemotherapy, prompted us to develop and identify new molecules, such as pyrano [2,3- 
EXPERIMENTAL
All melting points were measured on an Electrothermal 9100 series digital melting point apparatus (Shimadzu, Japan). Microanalytical data were obtained with a Vario Elementar apparatus (Shimadzu). Elemental analyses of all compounds were within ± 0.4 % of the theoretical values. Physicochemical data are given in Table I . The IR spectra (KBr) were recorded on a Perkin Elmer 1650 spectrometer (USA). 1 H NMR spectra were recorded on a JEOL EX-300 and a JEOL ECA-500 (Japan). Chemical shift s were expressed in ppm relative to SiMe 4 as internal standard and DMSO-d 6 as solvent. Mass spectra were recorded on a 70 ev EI Ms-QP 1000 EX (Shimadzu). Spectral data are given in Tables II and III . Thin layer chromatography (chloroform/methanol, 8:2) indicated the formation of pure compounds. Compounds ethyl-3-(2-carbamothioyl-hydrazinylidene) butanoate (1) and arylidene malononitriles (2a,b) were obtained using the procedures reported elsewhere (17, 18) . Ethyl acetoacetate, thiosemicarbazide, 1-bromo-2,3,5-tri-O-acetyl-α-D-ribo-/or xylo and arabinofuranose, 2,3,4,6-tetra-O-acetyl-α-D-gluco-and galacto pyranosyl bromide were purchased from Sigma-Aldrich (USA). Ofl oxacine, miconazole and doxorubicin disks were supplied by the Pasteur Laboratory (Giza, Egypt). [2,3-c] pyrazole -5-carbonitriles (3a,b) . General procedure. -Ethyl-3-(2-carbamo-thioylhydrazineylidene)-butanoate (3) (2.03 g, 10 mmol) and then arylidene malononitrile (2a,b) (10 mmol) were added into a sodium ethoxide solution (20 mL). The reaction mixture was heated under refl ux for 6 h. The product obtained was crystallized from an appropriate solvent to produce 3a,b, respectively, in high yields. [2,3 --c] pyrazole-5-carbonitriles (4a,b). General procedure. -The compounds were obtained from 3a,b and p-chlorobenzaldehyde in ethanol/piperidine. The reaction mixture was heated -f and 7a-d) . General procedure. -To a solution of 4a,b (0.01 mol) in 5 mL of aqueous potassium hydroxide (0.01 mol), a solution of 1-bromo-2,3,5-tri-O-acetyl-α-D-ribo-/or xylo and arabinofuranose or 2,3,4,6-tetra-Oacetyl-α-D-gluco-/or galacto and mannosopyranosyl bromide (0.015 mol) in acetone (40 mL) was added. The reaction mixture was stirred at room temperature for 24 h (under TLC control). The solvent was evaporated under reduced pressure at 40 o C, the crude product was fi ltered off and washed with distilled water to remove the KBr formed. The product was dried and crystallized from the proper solvent to produce 5a-f and 7a-f, respectively.
6-(4-Chloro-phenylmethylenehydrazone)-4-substituted phenyl-3-methyl-1,4-dihydro pyra no
General procedure. -Dry gaseous ammonia was passed through a solution of acetylated compounds 5a-f or 7a-d (1.0 mmol) in dry methanol (20 mL) at room temperature for 10 min. The mixture was stirred overnight. The resulting mixture was then evaporated under reduced pressure to aff ord a solid residue, which was crystallized from appropriate solvent to aff ord 6a-f and 8a-d, respectively.
Ethyl [5-cyano-4-(4-substituted-phenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazol-6-yl] imido-formates (9a,b)
. General procedure. -To a mixture of triethyl orthoformate (0.01 mol) and acetic anhydride (20 mL), compounds 5a,b (0.01 mol) were added and the reaction mixture was refl uxed for 5 h. The solvent was removed under reduced pressure and the separated solid was recrystallized from appropriate solvent to give 9a,b. [4',3':5,6] pyrano [2,3- 
4-(4-Substituted-phenyl)-5-imino-3-methyl-1,4-dihydropyrazolo
-To a solution of 9a,b (0.01 mol) in absolute ethanol (50 mL), hydrazine hydrate (0.01 mol) was added. The reaction mixture was refl uxed for 2 h, concentrated, cooled, and the solid product that separated out was fi ltered off and recrystallized from appropriate solvent to give 10a,b. [4',3':5,6] pyrano [3,2-e] [1, 2, 4] triazolo [1,5-c] 
2-(Penta-O-acetyl/tetra-O-acetyl-glycosyl)-11-(4-fl orophenyl)-10-methyl-8,11-dihydropyrazolo-

pyrimidines (11a-d and 13a-d).
-A solution from each of 10a,b (10 mmol) and aldopentose/aldohexose (10 mmol) in a mixture of acetic anhydride-acetic acid (1:1) (50 mL) was stirred under refl ux for 3-5 h. The mixture was then extracted several times with chloroform (150-200 mL). Aft er removal of chloroform under reduced pressure, the residue (intermediates 11a-d, 13a-d) was processed in the next step without identifi cation. [4',3':5,6] pyrano [3,2- (10 mmol) (sodium metal in methanol, 100 mL) was stirred at room temperature for 24 h and then neutralized with hydrochloric acid solution (pH control). The precipitate formed was fi ltered off , washed with cold water, dried and crystallized from ethanol (60-100 mL) to obtain 12a-d, and 14a-d, respectively. Table III . 13 
2-(Glycosyl)-11-(4-florophenyl)-10-methyl-8,11-dihydropyrazolo
C NMR data of newly synthesized compounds
Compd. 13 4a,b, 6a,b,d, 8a,b,d, 10a,b, 12a,d and 14a,b,d were tested in vitro against Gram-positive bacteria Bacillus subtilis NCTC-1040, Staphylococcus aureus NCTC-7547, Gram-negative bacteria Escherichia coli NCTC-10416, Sarcina lutea ATCC-954 and fungal strains Candida albicans ATCC-14154 and Aspergillus fl avus ATCC-23554. All microorganisms were purchased from the American Type Culture Collection (Manassas, VA, USA). The compounds were dissolved in DMSO (5 mg mL -1 ) and tested for antimicrobial activity by the agar disk diff usion technique (19) using a 1-cm microplate-well diameter and a 100 μL of each concentration. Compound impregnated disks were placed on an agar plate containing a standard suspension of microorganisms. The plate was incubated for 24 h at 35 °C. The diameters of the zones of inhibition were measured with calipers or automated scanners and were compared with those of the standards. Ofl oxacine (50 μg mL -1 ) and miconazole (50 μg mL -1 ) were used as standards for antibacterial and antifungal activity, respectively. The observed zones of inhibition are shown in Table IV. The minimal inhibitory concentration (MIC) of the test compounds was determined by the agar streak dilution method (20) . Stocks of synthesized compounds were prepared by dissolving 1 mg in 1 mL DMSO and diluted to the desired concentration. Diff erent concentrations of the synthesized compounds were mixed with known quantities of mol-
Ofl o x a c i n e 2 5 2 5 2 5 2 5 --Inhibition zone: 6-10 mm -slight activity, 11-15 mm -moderate activity, > 15 mm -high activity ten sterile agar medium. About 15 mL of the medium containing the test compound was poured into a sterile Petri dish and the medium was allowed to solidify. Microorganisms were then streaked one by one on the agar plates. Aft er streaking, all the plates were incubated at 37 °C for 24 and 48 h for antimicrobial and antifungal activity, respectively. The MIC values are shown in Table IV .
Antitumor activity. -Some of the synthesized compounds, namely, pyrazolo N-nucleoside (6a,b,d, 8a,d) , and C-glycoside of triazolopyrimidine derivatives 12a and 14a were tested for in vitro anticancer activity against three human cancer cell lines [liver cancer (HepG2), colon cancer (HT29), breast adenocarcinoma (MCF-7)] by the MTT assay. The three human cancer cell lines were provided by the National Cancer Institute (NCI, Cairo, Egypt). Their growth as a monolayer was maintained in RPMI-1640 medium supplemented with 5 % heat inactivated FBS (fetal bovine serum), 2 mmol L -1 glutamine and antibiotics (penicillin 100 U mL -1 , streptomycin 100 μg mL , followed by 24-h incubation. The eff ect of the vehicle solvent DMSO on the growth of these cell lines was evaluated by exposing un- treated control cells to the maximum concentration (0.5 %) of DMSO used in each assay. The eff ect of compounds on in vitro growth of human tumor cell lines was evaluated according to the procedure adopted by the National Cancer Institute (NCI, USA) using sulforhodamine B as protein binding dye to assess cell growth (21) . Cells growing exponentially in 96-well plates were then exposed for 48 h to fi ve serial concentrations of each compound, starting from a maximum concentration of 150 μg mL -1
. Aft er this exposure period, adherent cells were fi xed, washed and stained. The bound stain was solubilized and the absorbance was measured and the growth inhibition of 50 % (GI 50 ) was calculated (22) . Doxorubicin was used as a reference compound (Table VI) . RESULTS 
AND DISCUSSION
Chemistry
The fi rst step of our strategy was condensation of thiosemicarbazide (1) with ethyl acetoacetate 2 in ethanol, in the presence of triethylamine, to aff ord ethyl-3-(2-carbmothioyl-hydrazinylidene) butanoate (1) Table IV ) showed good activities atributable to the presence of the electron withdrawing hydroxyl groups in pyranozyl moeity. Other newly synthesized compounds exhibited slight antibacterial activity, and inactive against fungi compared to the reference drug (miconazole). Scheme 4 Antitumor activity and structure activity relationship 
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